|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Operating activities | |||||
| Loss for the period | |||||
| Adjustments to reconcile net loss for the period to net cash flows: | |||||
| Depreciation of property, plant and equipment | |||||
| Depreciation of right-of-use assets | |||||
| Finance (income)/expense, net | |||||
| Share-based compensation expense | |||||
| Change in net employee defined benefit liability | |||||
| Interest expense | |||||
| (Gain)/loss on lease modifications | |||||
| (Gain)/loss on sale of fixed assets | |||||
| Changes in working capital: | |||||
| (Increase)/decrease in prepaid expenses | |||||
| (Increase)/decrease in accrued income | |||||
| (Increase)/decrease in accounts receivable | |||||
| (Increase)/decrease in other current receivables | |||||
| (Decrease)/increase in accrued expenses | |||||
| (Decrease)/increase in deferred contract revenue, short-term | |||||
| (Decrease)/increase in deferred income | |||||
| (Decrease)/increase in trade and other payables | |||||
| (Decrease)/increase in deferred contract revenue, long-term | |||||
| Cash provided by/(used in) operating activities | |||||
| Interest received | |||||
| Interest paid | |||||
| Finance expenses paid | |||||
| Net cash flows provided by/(used in) operating activities | |||||
| Investing activities | |||||
| Short-term financial assets, net | |||||
| Purchases of property, plant and equipment | |||||
| Proceeds from sale of property, plant and equipment | |||||
| Rental deposits | |||||
| Net cash flows provided by/(used in) investing activities | |||||
| Financing activities | |||||
| Proceeds from issuance of convertible loan | |||||
| Transaction costs on issuance of shares | |||||
| Proceeds from public offerings of common shares, net of underwriting fees and transaction costs | |||||
| Proceeds from sale of treasury shares in public offerings, net of underwriting fees and transaction costs | |||||
| Proceeds from issuance of common shares - asset acquisition, net of transaction costs | |||||
| Proceeds from issuance of common shares - equity plan, net of transaction costs | |||||
| Transaction costs and stamp duty associated with the public offerings of common shares previously recorded in Accrued expenses | |||||
| Transaction costs associated with the sale of treasury shares in public offering previously recorded in Accrued expenses | |||||
| Principal payments of lease obligations | |||||
| Transaction costs associated with issuance of shares in relation to asset acquisition previously recorded in Accrued expenses | |||||
| Net cash flows (used in)/provided by financing activities | |||||
| Net increase/(decrease) in cash and cash equivalents | |||||
| Cash and cash equivalents at January 1 | |||||
| Exchange gain/(loss) on cash and cash equivalents | |||||
| Cash and cash equivalents at December 31 | |||||
| Supplemental non-cash activity | |||||
| Capital expenditures in Trade and other payables or Accrued expenses | |||||
| Issuance of shares for purchase of IPR&D asset in asset acquisition | |||||
| Transaction costs associated with issuance of shares in relation to the asset acquisition recorded in Accrued expenses | |||||
| Settlement of convertible notes recorded within Shareholders' equity | |||||
| Transaction costs and stamp duty associated with the public offerings of common shares recorded in Accrued expenses | |||||
| Transaction costs associated with the sale of treasury shares in public offering recorded in Accrued expenses | |||||
Loading...